Skip to main content

Table 1 Summary table of study characteristics

From: Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations

Author year

Country

Perspective

Time horizon

MHT duration base-case

MHT type

Discount Rate (%)

Year of costs

Cost per QALY

CE?

CIF?

Salpeter et al. 2009 [41]

USA

Societal

lifetime

15 years

E + P&E (pooled data)

3

2006

Age 50: $2,438;

Yes

Yes

Age 65: $27,953

No

Yes

Lekander et al. 2009 [42]

UK

Health care

50 years

5 years

E + P(+U)

E(-U)

3

2006

Age 50:

 

Yes

£580(+U)a

Yes

 

£205(-U)a

Yes

 

Lekander et al. 2009 [43]

USA

Societal

50 years

5 years

E + P(+U)

E(-U)

3

2006

Age 50:

 

Yes

$2,803(+U)

Yes

 

$295(- U)

Yes

 

Ylikangas et al. 2007 [44]

Finland

Health care

9 years

9 years

E + P(+U)

3

2003/2004

Age 50–70:

 

Yes

€2,996(+U)

Yes

 

(≤5 y MHT);

  

€4613(+U)

Yes

 

(≤9 y MHT);

  

Zethraeus et a.l 2005 [45]

Sweden

Societal

50 years

5 years

E + P(+)

E(-U)

3

2003

Age 50:

 

Yes

SEK 12,807 (+U)

Yes

 

SEK 8,266(- U);

Yes

 

Age 55:

 

Yes

SEK 10,844 (+U)

Yes

 

SEK 7,960(- U);

Yes

 

Age 60:

 

Yes

SEK 9,159(+U)

Yes

 

SEK 11,043(-U);

Yes

 
  1. Abbreviations: CE cost-effective, CIF declared potential for perceived conflict of interest, E estrogen-only MHT, MHT menopausal hormone therapy, P progestin, + U women with a uterus, -U women without a uterus
  2. aEquivalent amounts in US dollars: $1072 (£580) and $379 (£205). Rate = 1.8485, 30/06/2006